Over the past year, investors have been disappointed with Pfizer as the company's stock experienced a significant decline of 28.8%. This decline can be attributed, in part, to the anticipated drop in sales for Pfizer's COVID-19 vaccine, Comirnaty, and its antiviral treatment, Paxlovid. However, there is an overlooked aspect that investors have failed to recognize:...
They're buying Seagen for $43 billion so they can build an anti-cancer franchise. They need this. Pfizer has a strong pipeline, but when will they get behind their migraine drug, which was part of an acquisition? They're doing nothing with it.
When I began research for this post I expected to be giving the bull case for Pfizer. It's the type of stock I like - a household name oozing with quality and prestige, a strong moat, beaten up with strongly bearish sentiment with multiple factors pointing towards recovery, with short term technical support and long term positive fundamental outlook. I like to...
This is a make or break moment for NYSE:PFE Close this and next week below we sell and look for that next level. But we should be seeing a short squeeze "soon"(1-2 weeks).
NYSE:PFE Pfizer Inc. (PFE) is a leading pharmaceutical company with a diverse portfolio of drugs and products, including vaccines, oncology, and rare disease treatments. The successful rollout of COVID-19 vaccines has been a significant driver of Pfizer's revenue growth, with revenue increasing from HKEX:41 billion in 2020 to HKEX:81 billion in 2021 and...
The price has been traded in a downnsloping channel . We expect the bounce from the donwsloping support. Spelucative long position: entry: 38,43 target: 47,82 stop loss: 37,49
pfizer is gonna make wave c for target TASE:49 at least and HKEX:52
The PFE stock, Pfizer, Inc., looks like is about to take a deep dive... Going red... Let's have a look! The most obvious signal is the weekly candle today moving below EMA50, telling us that this stock is preparing to drop for months. Pfizer, Inc. peaked December 2021. In mid-December 2022 PFE printed the inverted hammer bearish candlestick pattern or shooting...
You may be familiar with the negative sentiment surrounding Pfizer, with many citing the company's heavy reliance on its COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid as a cause for concern. In addition to this, several of Pfizer's top-selling drugs will face patent expirations in the near future, leading many to believe that the company's stock will...
Buy Feb-24-23 43.5 Calls @ 0.1 Limit to Open (Weekly) Buy Mar-24-23 47 Calls @ 0.11 Limit to Open (Monthly (W))
6M Chart, PFE , on February 6, 2023, the signals on MACD have been steadily moving NE, after piercing below the histogram on July 2012; On July 2021, reached its ATH (All Time High); The RSI signal bounced over 70 and is now facing SE to test the line of 50, after bouncing up from it on January 2020; The price has been steadily falling since the ATH, from $60 to...
#Pfizer has been oversold for some time. Today's gap down on UBS downgrade could be the seller exhaustion and potential bounce to come. Target 1 - $46.5 Target 2 - $47.67 Target 3 - $51 Long term - $60 Risk - fall to $41. —— Trade is done when it hit one of the target or stop loss is hit. Disclaimer: Trading note. Not an investment advice.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance,...
The Chart currently shows Bullish signal as per these indicators: 1. Bullish Falling Wedge Chart Pattern 2. Bullish Divergence ( RSI ) If the upper trendline is broken can expect further upside potential.
#LUPIN NSE: LUPIN CMP: 756 TP: 910 SL: 700 TF: <6m RR > 3 times Return > 20% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE APOLLOHOSP FORTIS AARTIDRUGS Factors: BULLISH WEDGE BREAKOUT Trend Following Rising...
#AUROPHARMA NSE: AUROPHARMA CMP: 437 TP: 535 SL: 400 TF: <6m RR > 3.5 times Return > 22% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest...
#GLENMARK NSE: GLENMARK CMP: 440 TP: 515 SL: 400 TF: <6m RR > 2 times Return > 17% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising...
#CIPLA NSE: CIPLA CMP: 1128 TP: 1250 SL: 1080 TF: <6m RR > 2.5 times Return > 11% THYROCARE CNXPHARMA LUPIN NSE: CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest...